David Foureau
Carolinas Healthcare System
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David Foureau.
Liver International | 2017
Mark W. Russo; Nury Steuerwald; Harry James Norton; William E. Anderson; David Foureau; Naga Chalasani; Robert J. Fontana; Paul B. Watkins; Jose Serrano; Herbert L. Bonkovsky
Drug induced liver injury (DILI) is challenging because of the lack of biomarkers to predict mortality. Our aim was to describe miRNA changes in sera of subjects with acute idiosyncratic DILI and determine if levels of miRNAs were associated with 6 month mortality.
Drug Safety | 2016
Joshua B. French; Maurizio Bonacini; Marwan Ghabril; David Foureau; Herbert L. Bonkovsky
Medications to inhibit the actions of tumour necrosis factor alpha have revolutionized the treatment of several pro-inflammatory autoimmune conditions. Despite their many benefits, several serious side effects exist and adverse reactions do occur from these medications. While many of the medications’ potential adverse effects were anticipated and recognized in clinical trials prior to drug approval, several more rare adverse reactions were recorded in the literature as the popularity, availability and distribution of these medications grew. Of these potential adverse reactions, liver injury, although uncommon, has been observed in some patients. As case reports accrued over time and ultimately case series developed, the link became better established between this family of medicines and various patterns of liver injury. Interestingly, it appears that the majority of cases exhibit an autoimmune hepatitis profile both in serological markers of autoimmune liver disease and in classic autoimmune features seen on hepatic histopathology. Despite the growing evidence of this relationship, the pathogenesis of this reaction remains incompletely understood, but it appears to depend on characteristics of the medications and the genetic composition of the patients; it is likely more complicated than a simple medication class effect. Because of this still incomplete understanding and the infrequency of the occurrence, treatments have also been limited, although it is clear that most patients improve with cessation of the offending agent and, in certain cases, glucocorticoid use. However, more needs to be done in the future to unveil the underlying mechanisms of this adverse reaction.
Cancer Immunology, Immunotherapy | 2014
David Foureau; Asim Amin; Richard L. White; William E. Anderson; Chase P. Jones; Terry Sarantou; Iain H. McKillop; Jonathan C. Salo
Experimental hematology & oncology | 2018
Saad Z Usmani; Imran Khan; Christopher Chiu; David Foureau; Lawrence J. Druhan; Katherine Rigby; Tineke Casneuf; A. Kate Sasser
Blood | 2016
David Foureau; Qing Zhang; Tammy Cogdill; Adina S Wynn; Nury Steuerwald; Lawrence J. Druhan; Fei Guo; Katherine Rigby; Kyle Madden; James Thomas Symanowski; Belinda R. Avalos; Edward A. Copelan; Saad Z Usmani; Manisha Bhutani
Blood | 2015
Manisha Bhutani; David Foureau; Tammy Cogdill; Kyle Madden; Qing Zhang; Sarah A Baxter; Lawrence J. Druhan; Nilanjan Ghosh; Belinda R. Avalos; Edward A. Copelan; Saad Z Usmani
Journal of Clinical Oncology | 2018
Jonathan M. Gerber; Elizabeth Jandrisevits; Lawrence J. Druhan; Amanda Lance; Andrea E. Price; Virginia Thurston; Jing Ai; Thomas Gregory Knight; Brittany K. Ragon; Mitchell Turner; Edward H. Lipford; Edward A. Copelan; Michael R. Grunwald; Belinda R. Avalos; David Foureau
Clinical Lymphoma, Myeloma & Leukemia | 2017
Saad Z Usmani; Imran Khan; Christopher Chiu; David Foureau; Lawrence J. Druhan; Katherine Rigby; Tineke Casneuf; Kate Sasser
Blood | 2016
David Foureau; Qing Zhang; Lawrence J. Druhan; Nury Steuerwald; Fei Guo; Elizabeth Jandrisevits; Belinda R. Avalos; Danyu Sun; Ryan Jacobs; Nilanjan Ghosh
Blood | 2016
Jonathan M. Gerber; Lawrence J. Druhan; David Foureau; Elizabeth Jandrisevits; Amanda Lance; Andrea E. Price; Virginia Thurston; Jing Ai; Michael R. Grunwald; Edward H. Lipford; Belinda R. Avalos